Objective:To summarize the best evidence on nutrition management for colorectal cancer patients with colostomy both domestically and internationally.Methods:Based on the "6S" model, evidence on nutrition management of colorectal cancer patients with colostomy during hospitalization and at home was searched in national and international databases and specialized websites. The search period was from January 1, 2003 to December 31, 2023. Two researchers independently conducted a quality assessment of the literature, extracted and summarized evidence.Results:A total of 14 papers were included, including four clinical decisions, four guidelines, three evidence summaries, and three expert consensus. A total of 26 pieces of best evidence were formed in six areas of multidisciplinary nutrition support team, nutrition screening and assessment, preoperative nutrition pre-habilitation, postoperative nutrition support, discharge nutrition health education, and nutrition monitoring and follow-up.Conclusions:This study summarizes the best evidence for nutrition management of colorectal cancer patients with colostomy. It is recommended that healthcare professionals develop a systematic and scientific nutrition management strategy for colorectal cancer patients with colostomy, taking into account the actual clinical scenarios and patients' needs.

Objective:To summarize the best evidence on nutrition management for colorectal cancer patients with colostomy both domestically and internationally.Methods:Based on the "6S" model, evidence on nutrition management of colorectal cancer patients with colostomy during hospitalization and at home was searched in national and international databases and specialized websites. The search period was from January 1, 2003 to December 31, 2023. Two researchers independently conducted a quality assessment of the literature, extracted and summarized evidence.Results:A total of 14 papers were included, including four clinical decisions, four guidelines, three evidence summaries, and three expert consensus. A total of 26 pieces of best evidence were formed in six areas of multidisciplinary nutrition support team, nutrition screening and assessment, preoperative nutrition pre-habilitation, postoperative nutrition support, discharge nutrition health education, and nutrition monitoring and follow-up.Conclusions:This study summarizes the best evidence for nutrition management of colorectal cancer patients with colostomy. It is recommended that healthcare professionals develop a systematic and scientific nutrition management strategy for colorectal cancer patients with colostomy, taking into account the actual clinical scenarios and patients' needs.

Background::Coronavirus disease 2019 (COVID-19) has potential risks for both clinically worsening pulmonary hypertension (PH) and increasing mortality. However, the data regarding the protective role of vaccination in this population are still lacking. This study aimed to assess the safety of approved vaccination for patients with PH.Methods::In this national prospective cohort study, patients diagnosed with PH (World Health Organization [WHO] groups 1 and 4) were enrolled from October 2021 to April 2022. The primary outcome was the composite of PH-related major adverse events. We used an inverse probability weighting (IPW) approach to control for possible confounding factors in the baseline characteristics of patients.Results::In total, 706 patients with PH participated in this study (mean age, 40.3 years; mean duration after diagnosis of PH, 8.2 years). All patients received standardized treatment for PH in accordance with guidelines for the diagnosis and treatment of PH in China. Among them, 278 patients did not receive vaccination, whereas 428 patients completed the vaccination series. None of the participants were infected with COVID-19 during our study period. Overall, 398 patients received inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, whereas 30 received recombinant protein subunit vaccine. After adjusting for baseline covariates using the IPW approach, the odds of any adverse events due to PH in the vaccinated group did not statistically significantly increase (27/428 [6.3%] vs. 24/278 [8.6%], odds ratio = 0.72, P = 0.302). Approximately half of the vaccinated patients reported at least one post-vaccination side effects, most of which were mild, including pain at the injection site (159/428, 37.1%), fever (11/428, 2.6%), and fatigue (26/428, 6.1%). Conclusions::COVID-19 vaccination did not significantly augment the PH-related major adverse events for patients with WHO groups 1 and 4 PH, although there were some tolerable side effects. A large-scale randomized controlled trial is warranted to confirm this finding. The final approval of the COVID-19 vaccination for patients with PH as a public health strategy is promising.

PURPOSE: This study aimed to elucidate the molecular mechanisms of the anti-pancreatic fibrosis effects of matrine in rats. MATERIALS AND METHODS: Trinitrobenzene sulfonic acid was administrated to rats to establish a pancreatic fibrosis model. Rats were divided into four groups: Control, Sham, Model, and Matrine (n=8). Hematoxylin-eosin staining, Masson staining, and Azan staining were performed to evaluate pancreatic fibrosis. Expression of transforming growth factor-β1 (TGF-β1), α-smooth muscle actin (α-SMA), and collagen I in pancreatic tissues was evaluated by immunohistochemical staining. mRNA and protein levels of TGF-β receptor 1 (TβR1), TβR2, and Smad2 in pancreatic tissues were determined by RT-PCR and Western blot, respectively. RESULTS: In the model group, hyperplasia of glandules around the glandular ducts, mitochondrial swelling of acinous cells, and severe fibrosis were found. Interestingly, in the Matrine group, mitochondrial swelling was only found in a small number of acinous cells, and the fundamental structures of pancreatic tissues were intact. Moreover, pancreatic fibrosis was markedly alleviated. Comparing to the Sham group, expression of α-SMA, TGF-β1, and collagen I was sharply elevated in the Model group (p < 0.05); however, their expressions were much lower in the Matrine group, compared to the Model group (p < 0.05). Compared with the Sham group, mRNA and protein levels of Smad2, TβR1, and TβR2 in the Model group were notably raised (p < 0.05). However, their high expression was significantly downregulated in the Matrine group (p < 0.05). CONCLUSION: Matrine suppressed pancreatic fibrosis by regulating TGF-β/Smad signaling in rats.
Acinar Cells ; Actins ; Animals ; Blotting, Western ; Collagen ; Fibrosis* ; Hyperplasia ; Mitochondrial Swelling ; Rats* ; RNA, Messenger ; Signal Transduction

Objective To investigate the change of Gadd45?/? in HepG2 cells after UV radiation.Methods HepG2 cells were cultured in vitro followed by radiation with UV (254nm,10 J/m2)and harvested at 1,2,4 h respectively.The induction of Gadd45?/? mRNA by UV was analyzed using RT-PCR,and the induction of Gadd45?/? protein was determined by Western blot assay at the given interval simultaneously.Results The peak values of Gadd45?/? mRNA appeared at 4 h and 1h after induction respectively,while the both of the peak value of Gadd45?/? protein were found at 1h after UV radiation.Conclusion Gadd45?/? could be rapidly induced by UV radiation in HepG2 cells.

Objective To investigate the expression of Gadd45beta protein in human hepatocellular carcinoma(HCC) and its clinicopathologic significance.Methods Immunohistochemical method was used to detect the expressions of Gadd45beta in both hepatocellular carcinoma tissues and adjacent non-neoplastic liver tissues form 50 cases.Results The positive rates of Gadd45beta expression in the hepatocellular carcinoma tissues and adjacent non-neoplastic liver tissues were 26.0%(13/50) and 82.0%(41/50) respectively.There were significant difference for the positive rate between the two groups(P0.05).Conclusion Low expression of Gadd45beta protein in hepatocellular carcinoma tissues was exhibited,which may be related to hepatocarcinogenesis as well as biological behaviors and prognosis of HCC.